CNS tuberculosis.
Tuberculous meningitis is a rare, treatable neurologic disorder, in which early recognition is paramount because outcome depends greatly on the speed with which therapy is initiated. Patients with meningitis and CSF findings of low glucose, elevated protein and pleocytosis with evidence of tuberculosis elsewhere in the body (chest radiographs, positive tuberculin skin test), or a history of exposure to tuberculosis should be treated immediately with antituberculous medication. When the diagnosis remains uncertain, serial examination of the CSF for tuberculous organisms will often yield positive results. The CT scan may show hydrocephalus, a basilar arachnoiditis, or intraparenchymal lesions: tuberculomas. Hydrocephalus may respond to early shunting. Tuberculomas are best treated medically. Therapy should include INH and rifampin; ethambutol and pyrazinamide are suggested for the first 2 months of therapy. Steroids may be useful in diminishing the inflammatory response when altered consciousness or focal neurologic signs are present.
D001706:Biopsy; D002552:Cerebral Ventricles / Q000601:surgery; D002555:Cerebrospinal Fluid / Q000032:analysis / Q000166:cytology; D004977:Ethambutol / Q000627:therapeutic use; D006801:Humans; D006821:Hyaluronoglucosaminidase / Q000627:therapeutic use; D007538:Isoniazid / Q000627:therapeutic use; D009422:Nervous System Diseases / Q000209:etiology; D011379:Prognosis; D011718:Pyrazinamide / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D013307:Streptomycin / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D014375:Tuberculoma / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology; D014390:Tuberculosis, Meningeal / Q000150:complications / Q000209:etiology* / Q000473:pathology / Q000628:therapy
D011718:Pyrazinamide; D004977:Ethambutol; D006821:Hyaluronoglucosaminidase; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin